Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/IRCT20210211050323N3
IRCT20210211050323N3Not yet recruitingPhase 2

Clinical trial to evaluate the effect of rosuvastatin as adjunctive therapy on cytochrome b-245 beta chain (CYBB) gene expression in patients with multiple sclerosis

Hamedan University of Medical Sciences0 sites40 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 2
Status
Not yet recruiting
Enrollment
40
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
20 years to 70 years (—)
Sex
All

Inclusion Criteria

  • •History of multiple sclerosis at least one year ago
  • •Radiographic findings of magnetic resonance imaging ( MRI ) consistent with the clinical diagnosis of multiple sclerosis
  • •No other concomitant inflammatory disease
  • •Bad cholesterol levels (low-density lipoprotein) less than 130 mg / dL
  • •No pregnancy and lactation
  • •The consistency of the main treatment of patients and the use of a specific type of drug
  • •Do not take medications other than standard treatments for multiple sclerosis that alter the levels of the factors under consideration.
  • •Do not use any combination with antioxidant effects in the past month.

Exclusion Criteria

  • •Existing evidence-based on increased patient disability
  • •Consumption of any combination, or drugs with antioxidant effects except prescription drugs
  • •The existence of any cognitive or behavioral disorders with an effect on the patient's cooperation

Investigators

Similar Trials

Recruiting
Phase 2
The effect of rosuvastatin in multiple sclerosisMultiple sclerosis
IRCT20210211050323N2Hamedan University of Medical Sciences40
Completed
Phase 2
The effect of rosuvastatin in multiple sclerosisMultiple sclerosis
IRCT20210211050323N1Hamedan University of Medical Sciences40
Active, not recruiting
Phase 1
A randomised placebo controlled trial of rosuvastatin in systemic lupus erythematosus. - RCT of statin in SLESystemic lupus erythematosus.MedDRA version: 13.1 Level: LLT Classification code 10042944 Term: Systemic lupus erythematosis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2006-006214-16-GBImperial College64
Completed
Not Applicable
A study to evaluate the efficacy of Rosuvastatin for patients with coronary plaque utilizing aggressive lipid lowering treatmentHypercholesterolemia
JPRN-UMIN000001223Kokura Memorial Hospital400
Recruiting
Phase 2
Rosuvastatin in patients with moderate brain traumaModerate traumatic brain injury.Diffuse traumatic brain injuryS06.2
IRCT20230627058603N2Esfahan University of Medical Sciences200